Using machine learning to predict how people diagnosed with major depressive disorder respond to treatment
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
J&J’s Spravato receives FDA label expansion for depression monotherapy
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
mic43m
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
India Today on MSN58m
US FDA approves new nasal spray for depression treatment: All about it
The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...
Hosted on MSN1h
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
Medindia1h
Brain Implant to Treat Mood Disorders Using Ultrasound
A brain implant using ultrasound shows promise for treating mood disorders like depression and anxiety with precision and ...
FOX 322h
FDA approves first-of-its-kind nasal spray to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...
pharmaphorum2h
J&J's Spravato gets another lift with new FDA approval
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
FDA Approves Nasal Spray for Depression
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
PipelineReview.com4h
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior ...
Daily7h
JnJ Spravato gets USFDA nod as monotherapy for adults with treatment-resistant depression
Titusville: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, ...